澳大利亚最大的戒烟试验使用Screen2Quit(临床应用程序)测试数字工具在帮助吸烟者戒烟方面的功效。 Australia's largest smoking cessation trial uses Screen2Quit, a clinical app, to test digital tools' effectiveness in helping smokers quit.

Miroma项目工厂开发了Screen2Quit(Screen2Quit), 这是澳大利亚最大的戒烟试验的临床级移动应用程序, Miroma Project Factory has developed Screen2Quit, a clinical-grade mobile app for Australia’s largest smoking cessation trial, part of the International Lung Screen Trial led by the University of Queensland. 根据我的QuitBuddy平台,该应用程序在多年随机控制的试验中使用,以评估基于应用程序的干预措施是否在帮助人们戒烟方面优于网站或控制条件。 Based on the My QuitBuddy platform, the app is used in a multi-year randomized controlled trial to assess whether app-based interventions outperform websites or control conditions in helping people quit smoking. 它具有本地iOS和Android版本,为数据和论坛节制提供安全的后端,以及将用户行为与匿名临床结果联系起来的一个独特的试用身份识别系统。 It features native iOS and Android versions, secure backends for data and forum moderation, and a unique trial ID system linking user behavior to anonymized clinical outcomes. 该应用程序跟踪参与、导航和退出规划,支持数字行为和停止成功方面的实时研究。 The app tracks engagement, navigation, and quit planning, supporting real-time research on digital behavior and cessation success. 它分两个阶段发展,包括地方化、主持论坛和持续的技术支持。 Developed in two phases, it includes localization, a moderated forum, and ongoing technical support. 此次试验由荷兰皇家卫生理事会资助,昆士兰州卫生局支持,旨在评估数字保健工具在解决吸烟这一可预防疾病的主要原因方面的效力。 The trial, funded by the NHMRC and supported by Queensland Health, aims to evaluate the effectiveness of digital health tools in addressing smoking, a leading cause of preventable disease.